Clinical trials of riluzole in patients with ALS

R. G. Miller*, J. P. Bouchard, P. Duquette, A. Eisen, D. Gelinas, Y. Harati, T. L. Munsat, L. Powe, J. Rothstein, P. Salzman, R. L. Sufit

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


Two double-blinded, placebo-controlled clinical trials of riluzole have now been carried out in more than 1,100 patients with ALS. The results of both studies show a modest benefit in prolonging survival that is statistically significant. These results led to the availability of this drug by the Food and Drug Administration for use in the United States beginning in early 1996. This is the first drug that has been available for ALS. It begins a new era in both basic and clinical research in an attempt to find a cure for this disease.

Original languageEnglish (US)
Pages (from-to)S86-S92
Issue number4 SUPPL.
StatePublished - Oct 1996

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Clinical trials of riluzole in patients with ALS'. Together they form a unique fingerprint.

Cite this